Early Parkinson's Disease


$75 per visit


52 weeks

Parkinson’s Disease Study I

Official Title

Early Parkinson's Disease

Study Summary

This multicenter, randomized, double-blind, placebo-controlled, Phase 2 study will evaluate the efficacy of intravenous RO7046015 versus placebo over 52 weeks in participants with early Parkinson's Disease (PD) who are untreated or treated with monoamine oxidase B (MAO-B) inhibitors since baseline. The study will consist of 2 parts: a 52-week, double-blind, placebo-controlled treatment period (Part 1) after which eligible participants will continue into an all-participants-on-treatment blinded dose extension for an additional 52 weeks (Part 2).

Eligibility and Recruitment Information

Recruitment Status Recruiting
Eligible Genders Both
Eligible Ages 40-80
Inclusion Diagnosed with Parkinson's Disease within the last 2 years; Requires that you are not on symptomatic therapy or a very low dose of selective medications.
Exclusion Clinical signs or past medical history indicating a Parkinson syndrome other than idiopathic PD, including but not limited to, progressive supranuclear gaze palsy, multiple system atrophy, drug-induced parkinsonism, essential tremor, primary dystonia
Start Date
Compensation $75 per visit
Location Orlando, FL

Study Information

Condition Early Parkinson's Disease
Study Phase Phase 2

Administrative Information

Study ID NCT03100149
Investigators Ira J Goodman, MD

Apply for this study

Please include your first name.
Please include your last name.
Please include a valid email address.
Thank you for applying.
Sorry, something wen't wrong. Please contact us for support.